Benefits
Ulcerative colitis maintenance (the studied indication of the medicinal product Mutaflor)
Multiple randomized trials show E. coli Nissle 1917 is comparable to mesalamine in preventing ulcerative colitis relapse during remission. One of the strongest probiotic-versus-standard-medication trial bases for any GI condition.
Chronic constipation relief
Some trials in adults with chronic constipation report improved stool frequency and consistency over weeks of use. The effect is modest and the overall evidence base is limited.
Irritable bowel syndrome (studied; trial evidence mixed)
Evidence in irritable bowel syndrome is limited and mixed. Some trials report modest symptom improvement, particularly in constipation-predominant IBS, but results are not consistent across subtypes.
Acute diarrhea in infants (a studied drug indication)
Pediatric trials show E. coli Nissle 1917 reduces duration of infectious diarrhea in infants. One of the better-evidenced single-strain probiotics for pediatric GI infection management.
Pathogen displacement mechanism
Nissle 1917 produces compounds that suppress pathogenic E. coli and other gut pathogens through competitive exclusion and antimicrobial peptide production. Mechanism contributes to its acute and chronic GI benefits.
Anti-inflammatory gut effects
Nissle 1917 strengthens gut barrier function, reduces inflammatory cytokines in colonic tissue, and modulates immune responses. The anti-inflammatory mechanism underlies its UC efficacy and distinguishes it from generic probiotics.
Distinguishing E. coli safety
Unlike disease-causing E. coli, Nissle 1917 lacks their classic virulence factors, though it does carry the pks genomic island encoding the genotoxin colibactin (see Safety). Used safely as a prescription drug in Germany for decades. Important distinction: the species name shouldn't deter use of this specific well-characterized strain.
Mechanism of action
Gut microbiota colonization in dysbiotic UC gut
EcN occupies niche space in dysbiotic gut microbiota typical of UC, competing with pathogenic Enterobacteriaceae. The colonization is transient but functionally meaningful during the treatment window.
Outer membrane vesicles (OMV) immunomodulation
EcN releases outer membrane vesicles carrying surface antigens that interact with intestinal immune cells, modulating dendritic cell and T cell responses without requiring direct bacterial-cell contact.
Tight junction integrity enhancement
EcN upregulates tight junction proteins (claudins, occludin, ZO-1) in the intestinal epithelium — supporting barrier function in the leaky-gut context of active IBD.
Mucin production stimulation
EcN stimulates goblet-cell mucin production, reinforcing the protective mucus layer that separates luminal bacteria from the epithelium.
Anti-inflammatory cytokine modulation
Reduced TNF-α, IL-6, and IL-8; increased IL-10. Shifts the cytokine balance toward anti-inflammatory in the gut mucosa — the proposed basis for the UC remission effect.
Colicin and microcin antimicrobial production
EcN produces colicins and microcins — antimicrobial peptides active against pathogenic E. coli and other Enterobacteriaceae. Direct competitive exclusion mechanism beyond niche occupation alone.
Iron-uptake siderophores (competitive exclusion)
EcN expresses high-affinity siderophores that scavenge iron from the gut lumen, depriving pathogenic Enterobacteriaceae of this essential nutrient.
Clinical trials
Clinical evidence on Escherichia coli (Mutaflor®) for the indications and outcomes described.
Clinical population described in trial publication.
Kruis W et al. 2004 (Gut). Randomized double-blind double-dummy trial in 327 UC patients. Mutaflor® 200 mg/day vs mesalazine 500 mg three times daily for 12 months. EcN equivalent to mesalazine in maintaining UC remission. The pivotal trial supporting ECCO guideline recognition as evidence-based for UC remission maintenance.
Clinical evidence on Escherichia coli (Mutaflor®) for the indications and outcomes described.
Clinical population described in trial publication.
Matthes H et al. 2010 (BMC Complement Altern Med 10:13, PMID 20398311). Double-blind trial in 90 patients with moderate distal UC given once-daily EcN enemas (10, 20 or 40 mL) or placebo for at least 2 weeks. By intention-to-treat the responder rate was NOT significantly higher with EcN than placebo (p=0.44); only a per-protocol dose-response correlation reached significance (p=0.045). Note this is rectal (enema) administration, a different route from the oral capsule.
Clinical evidence on Escherichia coli (Mutaflor®) for the indications and outcomes described.
Clinical population described in trial publication.
Park SK et al. 2022 (Korean J Intern Med 37(5):949-957, PMID 36068716, NCT04969679). Multicentre Korean double-blind placebo-controlled trial of EcN added to 5-ASA in 133 mild-to-moderate UC patients for 8 weeks. The primary endpoint (reaching an improved IBDQ quality-of-life score) did NOT differ from placebo (51.7% vs 51.7%). Some secondary endpoints favored EcN (more clinical response at 4 weeks, more endoscopic remission at 8 weeks). Funded by a research grant from BL&H Co., Ltd.